[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) Presents the unaudited condensed interim consolidated financial statements and management's discussion and analysis for the period ended June 30, 2025 [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements.) Presents unaudited condensed interim consolidated financial statements for Flexible Solutions International, Inc. as of June 30, 2025, and for the three and six-month periods then ended [Condensed Interim Consolidated Balance Sheets](index=5&type=section&id=%28a%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Balance%20Sheets%20at%20June%2030%2C%202025%20and%20December%2031%2C%202024.) Total assets slightly decreased to $58.2 million, while total liabilities decreased to $15.7 million, leading to increased stockholders' equity Consolidated Balance Sheet Summary (in USD) | Balance Sheet Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $31,092,253 | $34,575,857 | | **Total Assets** | $58,234,048 | $59,968,579 | | **Total Current Liabilities** | $9,151,454 | $11,861,667 | | **Total Liabilities** | $15,654,667 | $18,602,553 | | **Total Stockholders' Equity** | $42,579,381 | $41,366,026 | [Consolidated Statements of Operations (Three Months)](index=6&type=section&id=%28b%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20%28Loss%29%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024.) Q2 2025 sales increased to $11.4 million, driven by new R&D services revenue, resulting in higher net income and diluted EPS Q2 Financial Performance (in USD) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Total Sales | $11,367,132 | $10,528,739 | | Gross Profit | $5,385,266 | $3,939,095 | | Operating Income | $3,297,114 | $1,970,912 | | Net Income (attributable to FSI) | $2,028,912 | $1,289,796 | | Diluted EPS | $0.15 | $0.10 | - A new revenue stream from research and development services contributed **$2.5 million** in sales for Q2 2025, which was not present in Q2 2024[15](index=15&type=chunk) [Consolidated Statements of Operations (Six Months)](index=7&type=section&id=%28c%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024.) H1 2025 sales decreased to $18.8 million, but gross profit increased, with net income remaining stable at $1.75 million First Half Financial Performance (in USD) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Total Sales | $18,840,824 | $19,753,611 | | Gross Profit | $7,336,830 | $6,759,462 | | Operating Income | $3,227,957 | $2,736,743 | | Net Income (attributable to FSI) | $1,751,178 | $1,747,022 | | Diluted EPS | $0.13 | $0.14 | [Consolidated Statements of Cash Flows](index=8&type=section&id=%28d%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Cash%20Flows%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024.) Cash from operations decreased to $4.7 million in H1 2025, with funds primarily used for capital expenditures, debt repayment, and dividends Cash Flow Summary for Six Months Ended June 30 (in USD) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash from Operating Activities | $4,738,637 | $5,309,855 | | Net cash from Investing Activities | ($1,331,042) | ($1,236,697) | | Net cash from Financing Activities | ($3,709,588) | ($2,633,885) | | **Net Change in Cash** | **($32,639)** | **$1,501,614** | [Consolidated Statements of Stockholders' Equity](index=9&type=section&id=%28e%29%20Unaudited%20Condensed%20Interim%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024.) Stockholders' equity increased to $42.6 million by June 30, 2025, driven by net income and stock option exercises, offset by dividends - Total stockholders' equity increased to **$42,579,381** at June 30, 2025, up from **$41,366,026** at December 31, 2024[18](index=18&type=chunk) - The company paid dividends of **$1,274,753** during the first six months of 2025[18](index=18&type=chunk) [Notes to Financial Statements](index=11&type=section&id=%28f%29%20Notes%20to%20Unaudited%20Condensed%20Interim%20Consolidated%20Financial%20Statements%20for%20the%20Period%20Ended%20June%2030%2C%202025.) Provides detailed explanations of accounting policies, financial figures, and segment reporting for the interim consolidated financial statements - The company's business involves manufacturing and marketing specialty chemicals for water evaporation control (HEATSAVR®, WATERSAVR®) and thermal polyaspartate biopolymers (TPAs) for industrial and agricultural applications[23](index=23&type=chunk) - Revenue from research and development services is recognized over time as contractual performance obligations are satisfied[29](index=29&type=chunk) - The company's three primary customers accounted for **47%** of sales in the first six months of 2025, down from **50%** in the same period of 2024, with a single customer for R&D services accounting for **13%** of total sales[31](index=31&type=chunk) [Management's Discussion and Analysis (MD&A)](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operation.) Management discusses financial results for Q2 and H1 2025, covering sales performance, expenses, liquidity, and capital resources - The company operates through two main divisions: Energy and water conservation products (EWCP) and Biodegradable polymers (BCPA), which also includes nitrogen conservation products and R&D services[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk) - Key factors expected to affect future results include crude oil prices, oil and gas industry activity, drought conditions for agricultural sales, and potential tariffs on materials from China[86](index=86&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Product sales decreased in H1 2025, offset by new R&D services revenue, leading to increased gross profit percentage and mixed operating expenses Key Changes in Operations (Six Months Ended June 30, 2025 vs 2024) | Item | Change | Reason | | :--- | :--- | :--- | | EWCP & BCPA Product Sales | Decrease | Decreased customer orders | | R&D Services Sales | Increase | Successful project completed in 2025 | | Gross Profit % | Increase | Higher margin on R&D sales | | Consulting Expense | Decrease | Decreased reliance on consultants | | Professional Fees | Increase | Higher accounting and audit fees due to growth | | Interest Expense | Increase | Increased debt levels | - Customer concentration remains significant, with three customers accounting for **47%** of product sales in the first half of 2025, and a new R&D services customer (Company E) becoming a major revenue source[82](index=82&type=chunk)[83](index=83&type=chunk) [Capital Resources and Liquidity](index=26&type=section&id=Capital%20Resources%20and%20Liquidity) The company maintains strong liquidity with $21.9 million in working capital, primarily funding operations, capital expenditures, debt, and dividends Sources and Uses of Cash (Six Months Ended June 30) | Item (in USD) | 2025 | 2024 | | :--- | :--- | :--- | | Cash from operating activities | 4,738,637 | 5,309,855 | | Purchase of property and equipment | (1,331,042) | (1,663,697) | | Repayment of debt (net) | (2,576,556) | (1,039,438) | | Dividends paid | (1,274,753) | (1,255,053) | - Working capital was **$21,940,799** as of June 30, 2025, compared to **$22,714,190** at December 31, 2024[85](index=85&type=chunk) - The company does not anticipate any significant capital requirements for the twelve months ending June 30, 2026[87](index=87&type=chunk) [Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control - Based on an evaluation as of June 30, 2025, the Principal Executive and Financial Officer concluded that the company's disclosure controls and procedures are effective[89](index=89&type=chunk) - No changes occurred in the company's internal control over financial reporting during the three months ended June 30, 2025, that materially affected, or are reasonably likely to materially affect, these controls[90](index=90&type=chunk) [PART II. OTHER INFORMATION AND EXHIBITS](index=28&type=section&id=PART%20II.%20OTHER%20INFORMATION%20AND%20EXHIBITS) Presents other required information and a list of exhibits filed as part of the Form 10-Q report [Other Information](index=28&type=section&id=Item%205.%20Other%20Information.) No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025 - No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the quarter ended June 30, 2025[92](index=92&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20Exhibits.) Lists certifications by executive and financial officers, along with Inline XBRL data files, as part of the Form 10-Q report List of Exhibits | Number | Description | | :--- | :--- | | 31.1 | Certification of Principal Executive Officer (Sarbanes-Oxley Act §302) | | 31.2 | Certification of Principal Financial Officer (Sarbanes-Oxley Act §302) | | 32.1 | Certification of Principal Executive and Financial Officer (Sarbanes-Oxley Act §906) | | 101 | Inline XBRL Documents | | 104 | Cover Page Interactive Data File |

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting Contraception Four Commercially Available Solutions for Women on the Horizon Conference Call Toda ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-42139 Actuate Therapeutics, Inc. (Exact name of registrant as specified in its charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 000-53285 IVEDA SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 20-2222203 (State or other ...

Exhibit 99.1 Salt Lake City, Utah – August 14, 2025 – Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Recent Business Highlights: ● Company remains on track to initiate clinical evaluations for all tests in Co-Dx PCR platform* pipeline before year-end, and is currently training clinical evaluatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 1-36346 OXBRIDGE RE HOLDINGS LIMITED (Exact name of registrant as specified in its charter) | Cayman Islands | 98 ...

For the fiscal quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from _______________ to _______________ Commission File Number 001-40981 Cactus Acquisition Corp. 1 Ltd. (Exact name of registrant as specified in its charter) Cayman Islands 333-2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission File Number: 001-42280 Cayson Acquisition Corp (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction (IRS Employer of incorporation or organization) Identification Number) 205 W 37th St, New York, NY 10018 (Address of principal executive offices) (Zip code) For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number 001-40981 (State or other jurisdiction of incorporation) (Commission File Number) Securities registered pursuant to S ...